Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2019
Price : $35 *
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin
- Indications Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms CITHARE
- 04 Mar 2019 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Nov 2018 to 1 Mar 2019.
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.
- 20 Aug 2018 New trial record